Advanced search
Publication Cover
Autoimmunity Volume 56, 2023 - Issue 1
Submit an article Journal homepage
2,798
Views
2
CrossRef citations to date
0
Altmetric
Review Article

RNA N6-methyladenosine methylation and skin diseases

Yaqin Yua Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha, China;b Research Unit of Key Technologies of Diagnosis and Treatment for Immune-related Skin Diseases, Chinese Academy of Medical Sciences, Changsha, China;c Clinical Medical Research Center of Major Skin Diseases and Skin Health of Hunan Province, Changsha, ChinaORCID Iconhttps://orcid.org/0000-0003-4362-9178View further author information
ORCID Icon,
Shuang Lua Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha, China;b Research Unit of Key Technologies of Diagnosis and Treatment for Immune-related Skin Diseases, Chinese Academy of Medical Sciences, Changsha, China;c Clinical Medical Research Center of Major Skin Diseases and Skin Health of Hunan Province, Changsha, ChinaORCID Iconhttps://orcid.org/0000-0001-6434-2454View further author information
ORCID Icon,
Hui Jina Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha, China;b Research Unit of Key Technologies of Diagnosis and Treatment for Immune-related Skin Diseases, Chinese Academy of Medical Sciences, Changsha, China;c Clinical Medical Research Center of Major Skin Diseases and Skin Health of Hunan Province, Changsha, ChinaORCID Iconhttps://orcid.org/0000-0002-6621-9529View further author information
ORCID Icon,
Huan Zhua Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha, China;b Research Unit of Key Technologies of Diagnosis and Treatment for Immune-related Skin Diseases, Chinese Academy of Medical Sciences, Changsha, China;c Clinical Medical Research Center of Major Skin Diseases and Skin Health of Hunan Province, Changsha, ChinaView further author information
,
Xingyu Weia Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha, China;b Research Unit of Key Technologies of Diagnosis and Treatment for Immune-related Skin Diseases, Chinese Academy of Medical Sciences, Changsha, China;c Clinical Medical Research Center of Major Skin Diseases and Skin Health of Hunan Province, Changsha, ChinaORCID Iconhttps://orcid.org/0000-0001-6603-2636View further author information
ORCID Icon,
Tian Zhoua Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha, China;b Research Unit of Key Technologies of Diagnosis and Treatment for Immune-related Skin Diseases, Chinese Academy of Medical Sciences, Changsha, China;c Clinical Medical Research Center of Major Skin Diseases and Skin Health of Hunan Province, Changsha, ChinaORCID Iconhttps://orcid.org/0000-0002-9528-7942View further author information
ORCID Icon &
Ming Zhaoa Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha, China;b Research Unit of Key Technologies of Diagnosis and Treatment for Immune-related Skin Diseases, Chinese Academy of Medical Sciences, Changsha, China;c Clinical Medical Research Center of Major Skin Diseases and Skin Health of Hunan Province, Changsha, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1320-1093View further author information
ORCID Icon show all
Article: 2167983 | Received 26 Aug 2022, Accepted 08 Jan 2023, Published online: 28 Jan 2023

References

  • Tintle S, Shemer A, Suárez-Fariñas M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol. 2011;128(3):1–14.
  • Legartová S, Fagherazzi P, Goswami P, et al. Irradiation potentiates p53 phosphorylation and p53 binding to the promoter and coding region of the TP53 gene. Biochimie. 2023;204:154–168.
  • Ahn K. The role of air pollutants in atopic dermatitis. J Allergy Clin Immunol. 2014;134(5):993–999; discussion 1000.
  • Lonne-Rahm S, Sundström I, Nordlind K, et al. Adult Atopic dermatitis patients and physical exercise: a swedish questionnaire study. Acta Derm Venereol. 2014;94(2):185–187.
  • Hu S, Anand P, Laughter M, et al. Holistic dermatology: an evidence-based review of modifiable lifestyle factor associations with dermatologic disorders. J Am Acad Dermatol. 2022;86(4):868–877.
  • Hurd PJ. The era of epigenetics. Brief Funct Genomics. 2010;9(5–6):425–428.
  • Cantara WA, Crain PF, Rozenski J, et al. The RNA modification database, RNAMDB: 2011 update. Nucleic Acids Res. 2011;39(Database issue):D195–D201.
  • Meyer KD, Saletore Y, Zumbo P, et al. Comprehensive Analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell. 2012;149(7):1635–1646.
  • Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1974;71(10):3971–3975.
  • Dubin DT, Taylor RH. The methylation state of poly A-containing messenger RNA from cultured hamster cells. Nucleic Acids Res. 1975;2(10):1653–1668.
  • Jia G, Fu Y, Zhao X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7(12):885–887.
  • Dominissini D, Moshitch-Moshkovitz S, Schwartz S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485(7397):201–206.
  • Zhang H, Shi X, Huang T, et al. Dynamic landscape and evolution of m6A methylation in human. Nucleic Acids Res. 2020;48(11):6251–6264.
  • Chen T, Hao YJ, Zhang Y, et al. m(6)a RNA methylation is regulated by microRNAs and promotes reprogramming to pluripotency. Cell Stem Cell. 2015;16(3):289–301.
  • Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol Cell. 2016;63(2):306–317.
  • Liu J, Yue Y, Han D, et al. A METTL3–METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10(2):93–95.
  • Śledź P, Jinek M. Structural insights into the molecular mechanism of the m6A writer complex. eLife. 2016;5:e18434.
  • Ping XL, Sun BF, Wang L, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24(2):177–189.
  • Schwartz S, Agarwala SD, Mumbach MR, et al. High-Resolution mapping reveals a conserved, widespread, dynamic mRNA methylation program in yeast meiosis. Cell. 2013;155(6):1409–1421.
  • Horiuchi K, Kawamura T, Iwanari H, et al. Identification of wilms’ tumor 1-associating protein complex and its role in alternative splicing and the cell cycle. J Biol Chem. 2013;288(46):33292–33302.
  • Yue Y, Liu J, Cui X, et al. VIRMA mediates preferential m6A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 2018;4:10.
  • Pendleton KE, Chen B, Liu K, et al. The U6 snRNA m 6 a methyltransferase METTL16 regulates SAM synthetase intron retention. Cell. 2017;169(5):824–835.e14.
  • Wen J, Lv R, Ma H, et al. Zc3h13 Regulates nuclear RNA m6A methylation and mouse embryonic stem cell Self-Renewal. Mol Cell. 2018;69(6):1028–1038.e6.
  • Ma H, Wang X, Cai J, et al. N6-Methyladenosine methyltransferase ZCCHC4 mediates ribosomal RNA methylation. Nat Chem Biol. 2019;15(1):88–94.
  • Patil DP, Chen C, Pickering BF, et al. m6A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016;537(7620):369–373.
  • Růžička K, Zhang M, Campilho A, et al. Identification of factors required for m(6) a mRNA methylation in arabidopsis reveals a role for the conserved E3 ubiquitin ligase HAKAI. New Phytol. 2017;215(1):157–172.
  • Wang Y, Zhang L, Ren H, et al. Role of hakai in m6A modification pathway in drosophila. Nat Commun. 2021;12(1):2159.
  • Church C, Moir L, McMurray F, et al. Overexpression of fto leads to increased food intake and results in obesity. Nat Genet. 2010;42(12):1086–1092.
  • Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889–894.
  • Zhao X, Yang Y, Sun BF, et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell Res. 2014;24(12):1403–1419.
  • Wei J, Liu F, Lu Z, et al. Differential m(6)A, m(6)A(m), and m(1)a demethylation mediated by FTO in the cell nucleus and cytoplasm. Mol Cell. 2018;71(6):973–985.e5.
  • Fu Y, Jia G, Pang X, et al. FTO-mediated formation of N6-hydroxymethyladenosine and N6-formyladenosine in mammalian RNA. Nat Commun. 2013;4:1798.
  • Zheng G, Dahl JA, Niu Y, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49(1):18–29.
  • Liu N, Zhou KI, Parisien M, et al. N 6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. Nucleic Acids Res. 2017;45(10):6051–6063.
  • Liu N, Dai Q, Zheng G, et al. N6-methyladenosine-dependent RNA structural switches regulate RNA–protein interactions. Nature. 2015;518(7540):560–564.
  • Theler D, Dominguez C, Blatter M, et al. Solution structure of the YTH domain in complex with N6-methyladenosine RNA: a reader of methylated RNA. Nucleic Acids Res. 2014;42(22):13911–13919.
  • Shi H, Wang X, Lu Z, et al. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res. 2017;27(3):315–328.
  • Ries RJ, Zaccara S, Klein P, et al. m(6)a enhances the phase separation potential of mRNA. Nature. 2019;571(7765):424–428.
  • Zhang Z, Luo K, Zou Z, et al. Genetic analyses support the contribution of mRNA N(6)-methyladenosine (m(6)A) modification to human disease heritability. Nat Genet. 2020;52(9):939–949.
  • Lin S, Choe J, Du P, et al. The m 6 a methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell. 2016;62(3):335–345.
  • Mendel M, Delaney K, Pandey RR, et al. Splice site m6A methylation prevents binding of U2AF35 to inhibit RNA splicing. Cell. 2021;184(12):3125–3142.e25.
  • Wang X, Zhao BS, Roundtree IA, et al. N6-methyladenosine modulates messenger RNA translation efficiency. Cell. 2015;161(6):1388–1399.
  • Wang X, Lu Z, Gomez A, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117–120.
  • Li A, Chen Y, Ping X, et al. Cytoplasmic m6A reader YTHDF3 promotes mRNA translation. Cell Res. 2017;27(3):444–447.
  • Xiao W, Adhikari S, Dahal U, et al. Nuclear m 6 a reader YTHDC1 regulates mRNA splicing. Mol Cell. 2016;61(4):507–519.
  • Roundtree IA, Luo G, Zhang Z, et al. YTHDC1 mediates nuclear export of N6-methyladenosine methylated mRNAs. eLife. 2017;6:e31311.
  • Hsu PJ, Zhu Y, Ma H, et al. Ythdc2 is an N(6)-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017;27(9):1115–1127.
  • Alarcón CR, Goodarzi H, Lee H, et al. HNRNPA2B1 is a mediator of m6A-Dependent nuclear RNA processing events. Cell. 2015;162(6):1299–1308.
  • Cieniková Z, Damberger FF, Hall J, et al. Structural and mechanistic insights into poly(uridine) tract recognition by the hnRNP C RNA recognition motif. J Am Chem Soc. 2014;136(41):14536–14544.
  • Mccloskey A, Taniguchi I, Shinmyozu K, et al. hnRNP C tetramer measures RNA length to classify RNA polymerase II transcripts for export. Science. 2012;335(6076):1643–1646.
  • Huang H, Weng H, Sun W, et al. Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285–295.
  • Wu R, Li A, Sun B, et al. A novel m6A reader Prrc2a controls oligodendroglial specification and myelination. Cell Res. 2019;29(1):23–41.
  • Zhang F, Kang Y, Wang M, et al. Fragile X mental retardation protein modulates the stability of its m6A-marked messenger RNA targets. Hum Mol Genet. 2018:27–22.
  • Edupuganti VSRR, Geiger S, Lindeboom RGH, et al. N6-methyladenosine (m6A) recruits and repels proteins to regulate mRNA homeostasis. Nat Struct Mol Biol. 2017;24(10):870–878.
  • Meyer KD, Patil DP, Zhou J, et al. 5′ UTR m6A promotes cap-independent translation. Cell. 2015;163(4):999–1010.
  • Schwartz S, Mumbach MR, Jovanovic M, et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5’ sites. Cell Rep. 2014;8(1):284–296.
  • Wang Y, Wang J, Gao L, et al. An SRp75/hnRNPG complex interacting with hnRNPE2 regulates the 5′ splice site of tau exon 10, whose misregulation causes frontotemporal dementia. Gene. 2011;485(2):130–138.
  • Xu C, Wang X, Liu K, et al. Structural basis for selective binding of m6A RNA by the YTHDC1 YTH domain. Nat Chem Biol. 2014;10(11):927–929.
  • Berulava T, Rahmann S, Rademacher K, et al. N6-adenosine methylation in MiRNAs. PLoS One. 2015;10(2):e118438.
  • Alarcón CR, Lee H, Goodarzi H, et al. N6-methyladenosine marks primary microRNAs for processing. Nature. 2015;519(7544):482–485.
  • Yang Y, Fan X, Mao M, et al. Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Res. 2017;27(5):626–641.
  • Wang Y, Li Y, Toth JI, et al. N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells. Nat Cell Biol. 2014;16(2):191–198.
  • Batista PJ, Molinie B, Wang J, et al. m6A RNA modification controls cell fate transition in mammalian embryonic stem cells. Cell Stem Cell. 2014;15(6):707–719.
  • Geula S, Moshitch-Moshkovitz S, Dominissini D, et al. m6 a mRNA methylation facilitates resolution of naïve pluripotency toward differentiation. Science. 2015;347(6225):1002–1006.
  • Xi L, Carroll T, Matos I, et al. m6A RNA methylation impacts fate choices during skin morphogenesis. eLife. 2020;9:e56980.
  • Ear J, Lin S. RNA methylation regulates hematopoietic stem and progenitor cell development. J Genet Genomics. 2017;44(10):473–474.
  • Lin Z, Hsu PJ, Xing X, et al. Mettl3-/Mettl14-mediated mRNA N(6)-methyladenosine modulates murine spermatogenesis. Cell Res. 2017;27(10):1216–1230.
  • Ivanova I, Much C, Di Giacomo M, et al. The RNA m 6 a reader YTHDF2 is essential for the post-transcriptional regulation of the maternal transcriptome and oocyte competence. Mol Cell. 2017;67(6):1059–1067.e4.
  • Gao X, Shin Y, Li M, et al. The Fat mass and obesity associated gene FTO functions in the brain to regulate postnatal growth in mice. PLoS One. 2010;5(11):e14005.
  • McTaggart JS, Lee S, Iberl M, et al. FTO is expressed in neurones throughout the brain and its expression is unaltered by fasting. PLoS One. 2011;6(11):e27968.
  • Li L, Zang L, Zhang F, et al. Fat mass and obesity-associated (FTO) protein regulates adult neurogenesis. Hum Mol Genet. 2017;26(13):2398–2411.
  • Wang C, Cui G, Liu X, et al. METTL3-mediated m6A modification is required for cerebellar development. PLoS Biol. 2018;16(6):e2004880.
  • Yoon K, Ringeling FR, Vissers C, et al. Temporal control of mammalian cortical neurogenesis by m6A methylation. Cell. 2017;171(4):877–889.e17.
  • Ma C, Chang M, Lv H, et al. RNA m6A methylation participates in regulation of postnatal development of the mouse cerebellum. Genome Biol. 2018;19(1):68.
  • Lizama CO, Hawkins JS, Schmitt CE, et al. Repression of arterial genes in hemogenic endothelium is sufficient for haematopoietic fate acquisition. Nat Commun. 2015;6:7739.
  • Zhang C, Chen Y, Sun B, et al. m(6)a modulates haematopoietic stem and progenitor cell specification. Nature. 2017;549(7671):273–276.
  • Mapperley C, van de Lagemaat LN, Lawson H, et al. The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function. J Exp Med. 2021;218(3):e20200829.
  • Gao Y, Vasic R, Song Y, et al. m(6)a modification prevents formation of endogenous Double-Stranded RNAs and deleterious innate immune responses during hematopoietic development. Immunity. 2020;52(6):1007–1021.e8.
  • Vu LP, Pickering BF, Cheng Y, et al. The N(6)-methyladenosine (m(6)a)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017;23(11):1369–1376.
  • Wang H, Zuo H, Liu J, et al. Loss of YTHDF2-mediated m(6)A-dependent mRNA clearance facilitates hematopoietic stem cell regeneration. Cell Res. 2018;28(10):1035–1038.
  • Wang H, Hu X, Huang M, et al. Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation. Nat Commun. 2019;10(1):1898.
  • Han D, Liu J, Chen C, et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature. 2019;566(7743):270–274.
  • Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787–795.
  • Liu Z, Ma Y, Cui Q, et al. Toll-like receptor 4 plays a key role in advanced glycation end products-induced M1 macrophage polarization. Biochem Biophys Res Commun. 2020;531(4):602–608.
  • Tong J, Wang X, Liu Y, et al. Pooled CRISPR screening identifies m(6)a as a positive regulator of macrophage activation. Sci Adv. 2021;7(18):eabd4742.
  • Gu X, Zhang Y, Li D, et al. N6-methyladenosine demethylase FTO promotes M1 and M2 macrophage activation. Cell Signal. 2020;69:109553.
  • Dong L, Chen C, Zhang Y, et al. The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth. Cancer Cell. 2021;39(7):945–957.e10.
  • Li H, Tong J, Zhu S, et al. m6A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. Nature. 2017;548(7667):338–342.
  • Tong J, Cao G, Zhang T, et al. m6A mRNA methylation sustains treg suppressive functions. Cell Res. 2018;28(2):253–256.
  • Zhu Y, Zhao Y, Zou L, et al. The E3 ligase VHL promotes follicular helper T cell differentiation via glycolytic-epigenetic control. J Exp Med. 2019;216(7):1664–1681.
  • Ding C, Xu H, Yu Z, et al. RNA m(6)a demethylase ALKBH5 regulates the development of γδ T cells. Proc Natl Acad Sci U S A. 2022;119(33):e2091649177.
  • Zhou J, Zhang X, Hu J, et al. m(6)a demethylase ALKBH5 controls CD4(+) T cell pathogenicity and promotes autoimmunity. Sci Adv. 2021;7(25):eabg0470.
  • Zheng Z, Zhang L, Cui X, et al. Control of early B cell development by the RNA N6-Methyladenosine methylation. Cell Rep. 2020;31(13):107819.
  • Mishra A, Sullivan L, Caligiuri MA. Molecular pathways: interleukin-15 signaling in health and in cancer. Clin Cancer Res. 2014;20(8):2044–2050.
  • Song H, Song J, Cheng M, et al. METTL3-mediated m(6)a RNA methylation promotes the anti-tumour immunity of natural killer cells. Nat Commun. 2021;12(1):5522.
  • Ma S, Yan J, Barr T, et al. The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity. J Exp Med. 2021;218(8):e20210279.
  • Luo Q, Fu B, Zhang L, et al. Decreased Peripheral blood ALKBH5 correlates with markers of autoimmune response in systemic lupus erythematosus. Dis Markers. 2020;2020:1–11.
  • Luo Q, Rao J, Zhang L, et al. The study of METTL14, ALKBH5, andYTHDF2 in peripheral blood mononuclear cells from systemic lupus erythematosus. Mol Genet Genomic Med. 2020;8(9):e1298.
  • Wang Y, Jin H. Transcriptome-Wide m6A methylation in skin lesions from patients with psoriasis vulgaris. Front Cell Dev Biol. 2020;8:591629.
  • Zhao T, Sun D, Zhao M, et al. N6-methyladenosine mediates arsenite-induced human keratinocyte transformation by suppressing p53 activation. Environ Pollut. 2020;259:113908.
  • Dahal U, Le K, Gupta M. RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2. Melanoma Res. 2019;29(4):382–389.
  • Yue Z, Cao M, Hong A, et al. m(6)a methyltransferase METTL3 promotes the progression of primary acral melanoma via mediating TXNDC5 methylation. Front Oncol. 2021;11:770325.
  • Yang S, Wei J, Cui Y, et al. m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019;10(1):2782.
  • Jia R, Chai P, Wang S, et al. m6A modification suppresses ocular melanoma through modulating HINT2 mRNA translation. Mol Cancer. 2019;18(1):161.
  • Xu Y, He X, Wang S, et al. The m(6)a reading protein YTHDF3 potentiates tumorigenicity of cancer stem-like cells in ocular melanoma through facilitating CTNNB1 translation. Oncogene. 2022;41(9):1281–1297.
  • Zhou R, Gao Y, Lv D, et al. METTL3 mediated m6A modification plays an oncogenic role in cutaneous squamous cell carcinoma by regulating ΔNp63. Biochem Biophys Res Commun. 2019;515(2):310–317.
  • Orouji E, Peitsch WK, Orouji A, et al. Oncogenic Role of an epigenetic reader of m(6)a RNA modification: YTHDF1 in merkel cell carcinoma. Cancers (Basel). 2020;12(1):202.
  • Ye F, Chen ER, Nilsen TW. Kaposi’s Sarcoma-Associated herpesvirus utilizes and manipulates RNA N6-Adenosine methylation to promote lytic replication. J Virol. 2017;91(16):e00466–17.
  • Llabjani V, Hoti V, Pouran HM, et al. Bimodal responses of cells to trace elements: insights into their mechanism of action using a biospectroscopy approach. Chemosphere. 2014;112:377–384.
  • Chen H, Zhao T, Sun D, et al. Changes of RNA N6-methyladenosine in the hormesis effect induced by arsenite on human keratinocyte cells. Toxicol in Vitro. 2019;56:84–92.
  • Cayir A, Barrow TM, Guo L, et al. Exposure to environmental toxicants reduces global N6-methyladenosine RNA methylation and alters expression of RNA methylation modulator genes. Environ Res. 2019;175:228–234.
  • Zhao T, Li X, Sun D, et al. Oxidative stress: one potential factor for arsenite-induced increase of N6-methyladenosine in human keratinocytes. Environ Toxicol Pharmacol. 2019;69:95–103.
  • Jiang L, Hickman JH, Wang S, et al. Dynamic roles of p53-mediated metabolic activities in ROS-induced stress responses. Cell Cycle. 2015;14(18):2881–2885.
  • Gu S, Sun D, Dai H, et al. N6-methyladenosine mediates the cellular proliferation and apoptosis via microRNAs in arsenite-transformed cells. Toxicol Lett. 2018;292:1–11.
  • Bai L, Tang Q, Zou Z, et al. m6A demethylase FTO regulates dopaminergic neurotransmission deficits caused by arsenite. Toxicol Sci. 2018;165(2):431–446.
  • Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605–614.
  • Zhang B, Zhou T, Wu H, et al. Difference of IFI44L methylation and serum IFN-a1 level among patients with discoid and systemic lupus erythematosus and healthy individuals. J Transl Autoimmun. 2021;4:100092.
  • Zhang B, Liu L, Zhou T, et al. A simple and highly efficient method of IFI44L methylation detection for the diagnosis of systemic lupus erythematosus. Clin Immunol. 2020;221:108612.
  • Hong Y, Wu J, Zhao J, et al. miR-29b and miR-29c are involved in Toll-Like receptor control of Glucocorticoid-Induced apoptosis in human plasmacytoid dendritic cells. PLoS One. 2013;8(7):e69926.
  • Chafin CB, Regna NL, Hammond SE, et al. Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment. Int Immunopharmacol. 2013;17(3):894–906.
  • Li L, Fan Y, Leng R, et al. Potential link between m 6 a modification and systemic lupus erythematosus. Mol Immunol. 2018;93:55–63.
  • Sun HL, Zhu AC, Gao Y, et al. Stabilization of ERK-Phosphorylated METTL3 by USP5 increases m(6)a methylation. Mol Cell. 2020;80(4):633–647.
  • Xiong J, He J, Zhu J, et al. Lactylation-driven METTL3-mediated RNA m(6)a modification promotes immunosuppression of tumor-infiltrating myeloid cells. Mol Cell. 2022;82(9):1660–1677.e10.
  • Deng J, Zhang J, Ye Y, et al. N(6) -methyladenosine-Mediated upregulation of WTAPP1 promotes WTAP translation and wnt signaling to facilitate pancreatic cancer progression. Cancer Res. 2021;81(20):5268–5283.
  • Cho S, Lee G, Pickering BF, et al. mTORC1 promotes cell growth via m(6)A-dependent mRNA degradation. Mol Cell. 2021;81(10):2064–2075.e8.
  • Han H, Fan G, Song S, et al. piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL. Blood. 2021;137(12):1603–1614.
  • Zhang D, Ning J, Okon I, et al. Suppression of m6A mRNA modification by DNA hypermethylated ALKBH5 aggravates the oncological behavior of KRAS mutation/LKB1 loss lung cancer. Cell Death Dis. 2021;12(6):518.
  • Yue C, Chen J, Li Z, et al. microRNA-96 promotes occurrence and progression of colorectal cancer via regulation of the AMPKα2-FTO-m6A/MYC axis. J Exp Clin Cancer Res. 2020;39(1):240.
  • Yang X, Shao F, Guo D, et al. WNT/β-catenin-suppressed FTO expression increases m(6)a of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis. Cell Death Dis. 2021;12(5):462.
  • Yu J, Chai P, Xie M, et al. Histone lactylation drives oncogenesis by facilitating m(6)a reader protein YTHDF2 expression in ocular melanoma. Genome Biol. 2021;22(1):85.
  • Fang R, Chen X, Zhang S, et al. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun. 2021;12(1):177.
  • Zhao X, Ge L, Wang J, et al. Exploration of potential integrated models of N6-Methyladenosine immunity in systemic lupus erythematosus by bioinformatic analyses. Front Immunol. 2021;12:752736.
  • Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.
  • Liu J, Thatiparthi A, Martin A, et al. Prevalence of psoriasis among adults in the U.S. 2009-2010 and 2013-2014 national health and nutrition examination surveys. J Am Acad Dermatol. 2021;84(3):767–769.
  • Zeng C, Tsoi LC, Gudjonsson JE. Dysregulated epigenetic modifications in psoriasis. Exp Dermatol. 2021;30(8):1156–1166.
  • Xian J, Shang M, Dai Y, et al. N(6)-methyladenosine-modified long non-coding RNA AGAP2-AS1 promotes psoriasis pathogenesis via miR-424-5p/AKT3 axis. J Dermatol Sci. 2022;105(1):27–36.
  • Rahib L, Wehner MR, Matrisian LM, et al. Estimated Projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4):e214708.
  • Choe J, Lin S, Zhang W, et al. mRNA circularization by METTL3–eIF3h enhances translation and promotes oncogenesis. Nature. 2018;561(7724):556–560.
  • Zheng W, Li Y, Su Z, et al. EIF3H knockdown inhibits malignant melanoma through regulating cell proliferation, apoptosis and cell cycle. Exp Cell Res. 2021;402(1):112488.
  • Lin Y, Wang S, Liu S, et al. Identification and verification of molecular subtypes with enhanced immune infiltration based on m6A regulators in cutaneous melanoma. Biomed Res Int. 2021;2021:1–19.
  • Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78(2):237–247.
  • Mbbf A, Dmh B, Jin Q, et al. Merkel cell carcinoma incidence, trends, and survival rates among adults aged ≥50years from United States cancer Statistics - ScienceDirect. J Am Acad Dermatol. 2019;80(4):1154–1156.
  • Mamimandjiami AI, Mouinga-Ondémé A, Ramassamy J, et al. Epidemiology and genetic variability of HHV-8/KSHV among rural populations and kaposi’s sarcoma patients in Gabon, Central africa. Review of the geographical distribution of HHV-8 K1 genotypes in Africa. Viruses. 2021;13(2):175.
  • Ye F. RNA N-adenosine methylation (mA) steers epitranscriptomic control of herpesvirus replication. Inflammation Cell Signaling. 2017;4(3):e1604.
  • Selberg S, Blokhina D, Aatonen M, et al. Discovery of small molecules that activate RNA methylation through cooperative binding to the METTL3-14-WTAP complex active site. Cell Rep. 2019;26(13):3762–3771.e5.
  • Yankova E, Blackaby W, Albertella M, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593(7860):597–601.
  • Xu QC, Tien YC, Shi YH, et al. METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m(6)A-YTHDF2-dependent manner. Oncogene. 2022;41(11):1622–1633.
  • Zhang ZW, Teng X, Zhao F, et al. METTL3 regulates m(6)a methylation of PTCH1 and GLI2 in sonic hedgehog signaling to promote tumor progression in SHH-medulloblastoma. Cell Rep. 2022;41(4):111530.
  • Bedi RK, Huang D, Eberle SA, et al. Small-Molecule inhibitors of METTL3, the major human epitranscriptomic writer. ChemMedChem. 2020;15(9):744–748.
  • He Y, Wang W, Xu X, et al. Mettl3 inhibits the apoptosis and autophagy of chondrocytes in inflammation through mediating Bcl2 stability via Ythdf1-mediated m(6)a modification. Bone. 2022;154:116182.
  • Wang JN, Wang F, Ke J, et al. Inhibition of METTL3 attenuates renal injury and inflammation by alleviating TAB3 m6A modifications via IGF2BP2-dependent mechanisms. Sci Transl Med. 2022;14(640):k2709.
  • Huang Y, Su R, Sheng Y, et al. Small-Molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell. 2019;35(4):677–691.e10.
  • Liu Y, Liang G, Xu H, et al. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Cell Metab. 2021;33(6):1221–1233.e11.
  • Su R, Dong L, Li Y, et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell. 2020;38(1):79–96.e11.
  • Su R, Dong L, Li C, et al. R-2HG exhibits anti-tumor activity by targeting FTO/m(6)a/MYC/CEBPA signaling. Cell. 2018;172(1–2):90–105.e23.
  • He W, Zhou B, Liu W, et al. Identification of a novel Small-Molecule binding site of the fat mass and obesity associated protein (FTO). J Med Chem. 2015;58(18):7341–7348.
  • Qiao Y, Zhou B, Zhang M, et al. A novel inhibitor of the obesity-related protein FTO. Biochemistry. 2016;55(10):1516–1522.
  • Zhou P, Wu M, Ye C, et al. Meclofenamic acid promotes cisplatin-induced acute kidney injury by inhibiting fat mass and obesity-associated protein-mediated m(6)a abrogation in RNA. J Biol Chem. 2019;294(45):16908–16917.
  • Xiao L, Li X, Mu Z, et al. FTO Inhibition enhances the antitumor effect of temozolomide by targeting MYC-miR-155/23a cluster-MXI1 feedback circuit in glioma. Cancer Res. 2020;80(18):3945–3958.
  • Li N, Kang Y, Wang L, et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci USA. 2020;117(33):20159–20170.
  • Müller S, Bley N, Busch B, et al. The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancer. Nucleic Acids Res. 2020;48(15):8576–8590.
  • Mahapatra L, Andruska N, Mao C, et al. A novel IMP1 inhibitor, BTYNB, targets c-Myc and inhibits melanoma and ovarian cancer cell proliferation. Transl Oncol. 2017;10(5):818–827.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.